Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Atrimed Pharma Absorbs Dr. Narendra Chirmule, Former Head Of BioconBy: Commstrat Dr. Hrishikesh Damle, M.D- Atrimed Pharma said that "We are pleased to announce that Dr. Narendra Chirmule is with us now and will be assisting us at Atrimed, as we have exciting lead molecules for Covid, Psoriasis & snake venom neutralisation. In his new role Dr Chirmule will be guiding us through the next level of studies making them eligible for IND application (Investigational New Drug). Investigational new drug application is the procedure to submit research findings to DCGI (Drugs Controller General of India) for their approval" further he said that "Dr. Chirmule has deep expertise in the area of immunogenicity in biologics and has been involved in shaping the regulatory guidelines for biologics and biosimilars in EU & US." Prior to this, Dr. Chirmule has held leadership positions in Amgen (Thousand Oaks, CA) and Merck Vaccines (West Point, PA) has contributed to clinical development of vaccines and biopharmaceuticals. He did a PhD on development of a leprosy vaccine, from Cancer Research Institute, Mumbai with post-doctoral studies on pathogenesis of AIDS from Cornell University Medical College -North Shore Hospital, New York; teaching and research as assistant professor in gene therapy at the University of Pennsylvania. Philadelphia In addition to the experience he brings into Atrimed Dr. Chirmule is on the NIH Advisory committee for HIV Vacceines. Narendra Chirmule is the co-founder and CEO of SymphonyTech Biologics, a data Analytics Company focused on engineering solutions to biology. End
|
|